10x Genomics Reports Q3 Earnings with Revenue and EPS Beats
10x Genomics (TXG) reported third-quarter financial results that exceeded analyst expectations for both top and bottom lines. The company posted GAAP earnings per share of -$0.15, outperforming estimates by $0.11, while revenue reached $150.7 million, representing a 1.1% increase year-over-year and beating consensus by $2.85 million. As of September 30, 2026, the company maintained a strong liquidity position with $575.7 million in cash, cash equivalents, and marketable securities. These results suggest a stabilizing revenue trend despite ongoing net losses as the company continues its operations in the genomics sector.
Tickers: $TXG
Topics: cash position earnings beat revenue growth